{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:09:19Z","timestamp":1790392159431,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Standard therapy for elderly patients with acute myeloid leukemia (AML) consists of hypomethylating agents (HMAs) combined with venetoclax (VEN), administered long term until disease progression. However, several retrospective studies have shown that patients in complete remission (CR) who discontinued treatment electively or because of poor tolerance did not experience a negative impact on relapse-free or overall survival. Therefore, after obtaining informed consent, we offered treatment discontinuation to patients in CR after six months of HMA-VEN therapy. Here, we report the outcomes of seven consecutively treated patients who achieved CR between May 2021 and June 2025 and opted for discontinuation of therapy. Five of the seven patients showed clearance of somatic mutations to &lt;\u20091% and resolution of cytogenetic abnormalities. Six of the seven patients remain in continuous remission for 7\u201350 months. One patient with FLT3-ITD experienced relapse after 14 months and achieved a second hematologic remission after resuming HMA-VEN therapy. These findings suggest that treatment-free remission after time-limited HMA-VEN therapy may be a feasible approach in selected patients.<\/jats:p>","DOI":"10.1007\/s00277-026-07076-z","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T09:35:44Z","timestamp":1779442544000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Fixed-time treatment of elderly patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) using hypomethylating agents and venetoclax \u2013 a case series"],"prefix":"10.1007","volume":"105","author":[{"given":"Albrecht","family":"Lindemann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"G\u00f6ckel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Garcia-Pardillos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"7076_CR1","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V et al (2020) Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl J Med 383:617\u2013629. https:\/\/doi.org\/10.1056\/NEJMoa2012971","journal-title":"N Engl J Med"},{"key":"7076_CR2","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s41408-025-01346-1","volume":"15","author":"N Gangat","year":"2025","unstructured":"Gangat N, Dinardo CD (2025) Newly diagnosed acute myeloid leukemia in unfit patients: 2026 treatment algorithms. Blood Cancer J 15:139. https:\/\/doi.org\/10.1038\/s41408-025-01346-1","journal-title":"Blood Cancer J"},{"key":"7076_CR3","doi-asserted-by":"publisher","first-page":"3879","DOI":"10.1182\/bloodadvances.2022007083","volume":"6","author":"CC Chua","year":"2022","unstructured":"Chua CC, Hammond D, Kent A et al (2022) Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia. Blood Adv 6:3879\u20133883. https:\/\/doi.org\/10.1182\/bloodadvances.2022007083","journal-title":"Blood Adv"},{"key":"7076_CR4","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP et al (2022) International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood 140:1200\u20131228. https:\/\/doi.org\/10.1182\/blood.2022015850","journal-title":"Blood"},{"key":"7076_CR5","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1182\/blood.2024025409","volume":"144","author":"H D\u00f6hner","year":"2024","unstructured":"D\u00f6hner H, DiNardo CD, Appelbaum FR et al (2024) Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations. Blood 144:2169\u20132173. https:\/\/doi.org\/10.1182\/blood.2024025409","journal-title":"Blood"},{"key":"7076_CR6","doi-asserted-by":"publisher","first-page":"EVIDoa2200008","DOI":"10.1056\/EVIDoa2200008","volume":"1","author":"E Bernard","year":"2022","unstructured":"Bernard E, Tuechler H, Greenberg PL et al (2022) Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. NEJM Evid 1:EVIDoa2200008. https:\/\/doi.org\/10.1056\/EVIDoa2200008","journal-title":"NEJM Evid"},{"key":"7076_CR7","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR et al (2022) Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140:1345\u20131377. https:\/\/doi.org\/10.1182\/blood.2022016867","journal-title":"Blood"},{"key":"7076_CR8","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","volume":"108","author":"BD Cheson","year":"2006","unstructured":"Cheson BD, Greenberg PL, Bennett JM et al (2006) Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 108:419\u2013425. https:\/\/doi.org\/10.1182\/blood-2005-10-4149","journal-title":"Blood"},{"key":"7076_CR9","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41408-025-01269-x","volume":"15","author":"C Willekens","year":"2025","unstructured":"Willekens C, Bazinet A, Chraibi S et al (2025) Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients. Blood Cancer J 15:68. https:\/\/doi.org\/10.1038\/s41408-025-01269-x","journal-title":"Blood Cancer J"},{"key":"7076_CR10","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1111\/head.12246","volume":"53","author":"JJ Gagnier","year":"2013","unstructured":"Gagnier JJ, Kienle G, Altman DG et al (2013) The CARE guidelines: consensus-based clinical case reporting guideline development. Headache 53:1541\u20131547. https:\/\/doi.org\/10.1111\/head.12246","journal-title":"Headache"},{"key":"7076_CR11","doi-asserted-by":"publisher","first-page":"e756","DOI":"10.1016\/S2352-3026(22)00216-2","volume":"9","author":"A Bazinet","year":"2022","unstructured":"Bazinet A, Darbaniyan F, Jabbour E et al (2022) Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1\u20132 study. Lancet Haematol 9:e756\u2013e765. https:\/\/doi.org\/10.1016\/S2352-3026(22)00216-2","journal-title":"Lancet Haematol"},{"key":"7076_CR12","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1182\/blood.2024025464","volume":"145","author":"JS Garcia","year":"2025","unstructured":"Garcia JS, Platzbecker U, Odenike O et al (2025) Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromes. Blood 145:1126\u20131135. https:\/\/doi.org\/10.1182\/blood.2024025464","journal-title":"Blood"},{"key":"7076_CR13","unstructured":"VCV000435097.39 - ClinVar - NCBI. https:\/\/preview.ncbi.nlm.nih.gov\/clinvar\/variation\/435097\/. Accessed 10 Feb 2026"},{"key":"7076_CR14","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1182\/bloodadvances.2024015149","volume":"9","author":"RD Chow","year":"2025","unstructured":"Chow RD, Velu P, Deihimi S et al (2025) Persistent postremission clonal hematopoiesis shapes the relapse trajectories of acute myeloid leukemia. Blood Adv 9:1888\u20131899. https:\/\/doi.org\/10.1182\/bloodadvances.2024015149","journal-title":"Blood Adv"},{"key":"7076_CR15","doi-asserted-by":"publisher","first-page":"E63","DOI":"10.1002\/ajh.27180","volume":"99","author":"O Karrar","year":"2024","unstructured":"Karrar O, Abdelmagid M, Rana M et al (2024) Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival. Am J Hematol 99:E63\u2013E66. https:\/\/doi.org\/10.1002\/ajh.27180","journal-title":"Am J Hematol"},{"key":"7076_CR16","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41408-025-01270-4","volume":"15","author":"N Gangat","year":"2025","unstructured":"Gangat N, Tefferi A (2025) Venetoclax schedule in AML: 7 vs 14 vs 21 vs 28 days. Blood Cancer J 15:56. https:\/\/doi.org\/10.1038\/s41408-025-01270-4","journal-title":"Blood Cancer J"},{"key":"7076_CR17","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1002\/ajh.27417","volume":"99","author":"S Garciaz","year":"2024","unstructured":"Garciaz S, Dumas P-Y, Bertoli S et al (2024) Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatment. Am J Hematol 99:1870\u20131876. https:\/\/doi.org\/10.1002\/ajh.27417","journal-title":"Am J Hematol"},{"key":"7076_CR18","doi-asserted-by":"publisher","first-page":"4225","DOI":"10.1182\/blood-2023-178351","volume":"142","author":"H Pomares","year":"2023","unstructured":"Pomares H, Arribas I, Qui\u00f1ones T et al (2023) LONG-TERM Outcomes after Venetoclax-Hypomethylating Agent Combination Therapy Discontinuation, in Patients with ACUTE Myeloid Leukemia. Experience of a Single Center. Blood 142:4225. https:\/\/doi.org\/10.1182\/blood-2023-178351","journal-title":"Blood"},{"key":"7076_CR19","doi-asserted-by":"publisher","first-page":"5232","DOI":"10.1182\/blood-2025-5232","volume":"146","author":"R De G\u00f3mez","year":"2025","unstructured":"De G\u00f3mez R, Pomares H, Ramil L\u00f3pez G et al (2025) Real-world insights into venetoclax and\/or hypomethylating agent discontinuation in patients with Acute Myeloid Leukemia. Blood 146:5232\u20135232. https:\/\/doi.org\/10.1182\/blood-2025-5232","journal-title":"Blood"},{"key":"7076_CR20","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1056\/NEJMoa2004444","volume":"383","author":"AH Wei","year":"2020","unstructured":"Wei AH, D\u00f6hner H, Pocock C et al (2020) Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission. N Engl J Med 383:2526\u20132537. https:\/\/doi.org\/10.1056\/NEJMoa2004444","journal-title":"N Engl J Med"},{"key":"7076_CR21","unstructured":"H. Lee Moffitt Cancer Center and Research Institute (2026) Discontinuation of hypomethylating agent and venetoclax in patients with newly diagnosed acute myeloid leukemia (AML) who have achieved negative measurable residual disease (MRD). clinicaltrials.gov"},{"key":"7076_CR22","doi-asserted-by":"publisher","first-page":"S644","DOI":"10.1016\/S2152-2650(25)02083-X","volume":"25","author":"G Garcia-Manero","year":"2025","unstructured":"Garcia-Manero G, Platzbecker U, Fenaux P et al (2025) MDS-1497: Primary Analysis of the Randomized, Phase 3 VERONA Study of Venetoclax With Azacitidine Versus Placebo With Azacitidine in Patients With Treatment-Na\u00efve, Intermediate and Higher-Risk Myelodysplastic Syndromes. Clin Lymphoma Myeloma Leuk 25:S644\u2013S645. https:\/\/doi.org\/10.1016\/S2152-2650(25)02083-X","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07076-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07076-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07076-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T09:48:19Z","timestamp":1781344099000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-07076-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":22,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["7076"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07076-z","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"assertion":[{"value":"13 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics declaration"}},{"value":"was obtained from all individual participants included in the study. The participants have consented to the submission of the case report to the journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"292"}}